Yangjing Shugan decoction targets the Sirt1/Nrf2 antioxidant pathway and gut microbiota-metabolite axis to protect against premature ovarian failure
Frontiers in Pharmacology · 16.01.2026 · 16
DOI: 10.3389/fphar.2025.1722692 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 16.01.2026. Verfasst von Ling Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Hospital Changchun University of Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
This study aimed to assess the therapeutic potential of Yangjing Shugan decoction (YJSGD) in D-galactose (D-gal)-induced Premature Ovarian Failure (POF) mice and to elucidate its underlying mechanisms.
Methods
The main metabolites in YJSGD were characterized. A D-gal-induced POF mouse model was established and intervened with YJSGD at doses of 25, 50, and 100 mg/kg. A comprehensive analysis encompassing ovarian function, oxidative stress, inflammation, the Sirt1/Nrf2 pathway, gut microbiota, short-chain fatty acids (SCFAs), and serum metabolomics was conducted.
Results
The results demonstrated that YJSGD effectively restored estrous cyclicity, normalized serum estradiol (E2), follicle-stimulating hormone (FSH), and luteinizing hormone (LH) levels, and improved ovarian follicular development. YJSGD treatment also enhanced systemic antioxidant capacity and attenuated inflammation. Mechanistically, the therapeutic effects were associated with the upregulation of the Sirt1/Nrf2 signaling pathway in the ovary, as evidenced by increased protein expression of Sirt1, Nrf2, and HO-1, and suppressed Keap1. Furthermore, YJSGD ameliorated gut microbiota dysbiosis, promoted beneficial SCFAs production, and rectified serum metabolic disturbances involved in amino acid, lipid, and energy metabolism.
Conclusion
The results indicate that YJSGD is a promising multi-target agent for POF treatment, and its synergistic effects on reproductive, oxidative, and gut microbiota homeostasis provide a solid basis for its clinical application.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Affiliated Hospital Changchun University of Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China.
- Jilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun, China.
- School of Pharmaceutical Sciences, Changchun University of Chinese Medicine, Changchun, China.
- College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China.
- The Third Affiliated Hospital of Changchun University of Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China.
Zitieren
APA
Yang, L., Liu, L., Liu, J., Xu, M. R., Ren, J., Li, B., Jiao, L., Wei, Y., Wang, J., & Guo, Y. (2026). Yangjing Shugan decoction targets the Sirt1/Nrf2 antioxidant pathway and gut microbiota-metabolite axis to protect against premature ovarian failure. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1722692
Vancouver
Yang L, Liu L, Liu J, Xu MR, Ren J, Li B, et al. Yangjing Shugan decoction targets the Sirt1/Nrf2 antioxidant pathway and gut microbiota-metabolite axis to protect against premature ovarian failure. Frontiers in Pharmacology. 2026;16. doi:10.3389/fphar.2025.1722692
BibTeX
@article{Yang2026,
author = {Yang, Ling and Liu, Li and Liu, Junbo and Xu, Meng Ran and Ren, Jing and Li, Bo and Jiao, Lili and Wei, Yunyan and Wang, Jing and Guo, Yi},
title = {Yangjing Shugan decoction targets the Sirt1/Nrf2 antioxidant pathway and gut microbiota-metabolite axis to protect against premature ovarian failure},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {16},
doi = {10.3389/fphar.2025.1722692}
}
EUVIMED